Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia

Qing-Ming Yang,1,* Jung Yong Hong,2,* Young Hyeh Ko,3 Shek-Ying Lin,4 Wing-Yan Au,4 Moon Ki Choi,5 Silvia Park,6 Seok Jin Kim,6 Won Seog Kim6 1The First Affiliated Hospital of the People's Liberation Army General Hospital, Beijing, People's Republic of China; 2Department of Internal...

Full description

Bibliographic Details
Main Authors: Yang QM, Hong JY, Ko YH, Lin SY, Au WY, Choi MK, Park S, Kim SJ, Kim WS
Format: Article
Language:English
Published: Dove Medical Press 2014-09-01
Series:OncoTargets and Therapy
Online Access:http://www.dovepress.com/brentuximab-vedotin-for-relapsed-or-refractory-cd30-hodgkin-lymphoma-a-peer-reviewed-article-OTT

Internet

http://www.dovepress.com/brentuximab-vedotin-for-relapsed-or-refractory-cd30-hodgkin-lymphoma-a-peer-reviewed-article-OTT

Similar Items